Equity Profile

ALNY

ALNYLAM PHARMACEUTIC

Health CareBiotechnology$40.5B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies based on RNA interference (RNAi)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

$1.99

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market performance and future potential.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ALNY Q2-2026 Earnings Preview

Context

Company Snapshot

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies based on RNA interference (RNAi). With a market cap of $40 billion, it plays a significant role in the healthcare sector, particularly in addressing rare genetic diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+157.23%

Avg Stock Reaction

+1.45%

Last Quarter Recap

In Q1-2026, Alnylam reported an EPS of $1.99, significantly exceeding expectations by nearly 118%. The stock reacted positively, gaining 2.76% the following day.

Management Promises & Guidance

Continued focus on advancing RNAi therapies.
Commitment to expanding their product pipeline.
Plans to enhance operational efficiencies.

Expectations

Wall Street Expectations

Overall, expectations are high for Alnylam's upcoming earnings, especially given their strong track record of beating EPS estimates in recent quarters.

Bull Case

If Alnylam continues its trend of strong earnings surprises, it could lead to increased investor confidence and a significant stock price boost.

Bear Case

Conversely, any signs of slowing growth or failure to meet high expectations could lead to a sharp decline in stock price, especially given the high implied volatility.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.99

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

Revenue Growth

N/A

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market performance and future potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $1.99 as it has in previous quarters?

A continued trend of exceeding EPS estimates could reinforce investor confidence and drive the stock higher.

What updates will management provide on revenue growth and product pipeline?

Insights into revenue growth and advancements in their product pipeline will be crucial for assessing future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Alnylam's ability to sustain its growth trajectory, given its recent strong performance and innovative pipeline.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a higher volatility than historical averages, reflecting market uncertainty.

The positive stock reaction following previous earnings surprises suggests strong investor confidence.

Key Risk

If Alnylam's revenue growth shows signs of deceleration, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will set the tone for investor sentiment and expectations moving forward.

Bull Confirmed If

An EPS of $2.10 or higher would confirm the bullish case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.80 would signal potential weaknesses in the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±19.8%

Historical Avg

±6.4%

Pricing rich

The options market is pricing in a significant potential move, reflecting uncertainty and anticipation surrounding the earnings report.

Options are pricing ±19.8% while ALNY has averaged ±6.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

30.3%

Calls (21K)P/C Ratio: 0.89Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Alnylam beats expectations, history suggests the stock could rise by around 1.45%, confirming strong operational momentum.

In-Line / Cautious

A cautious inline report could lead to muted reactions, as investors weigh management's commentary against high expectations.

Miss

If the company misses expectations, history suggests a potential decline of around 6.65%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of new RNAi therapies in the pipeline.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on operational efficiencies and cost management strategies.
4Insights into market demand for their existing products.
5Any commentary on competitive landscape and market positioning.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies based on RNA interference (RNAi)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

$1.99

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market performance and future potential.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ALNY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+157.23%

Avg Stock Reaction

+1.45%

Last Quarter Recap

In Q1-2026, Alnylam reported an EPS of $1.99, significantly exceeding expectations by nearly 118%. The stock reacted positively, gaining 2.76% the following day.

Management Promises & Guidance

Continued focus on advancing RNAi therapies.
Commitment to expanding their product pipeline.
Plans to enhance operational efficiencies.

Expectations

Wall Street Expectations

Overall, expectations are high for Alnylam's upcoming earnings, especially given their strong track record of beating EPS estimates in recent quarters.

Bull Case

If Alnylam continues its trend of strong earnings surprises, it could lead to increased investor confidence and a significant stock price boost.

Bear Case

Conversely, any signs of slowing growth or failure to meet high expectations could lead to a sharp decline in stock price, especially given the high implied volatility.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.99

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

Revenue Growth

N/A

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market performance and future potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $1.99 as it has in previous quarters?

A continued trend of exceeding EPS estimates could reinforce investor confidence and drive the stock higher.

What updates will management provide on revenue growth and product pipeline?

Insights into revenue growth and advancements in their product pipeline will be crucial for assessing future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Alnylam's ability to sustain its growth trajectory, given its recent strong performance and innovative pipeline.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a higher volatility than historical averages, reflecting market uncertainty.

The positive stock reaction following previous earnings surprises suggests strong investor confidence.

Key Risk

If Alnylam's revenue growth shows signs of deceleration, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will set the tone for investor sentiment and expectations moving forward.

Bull Confirmed If

An EPS of $2.10 or higher would confirm the bullish case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.80 would signal potential weaknesses in the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±19.8%

Historical Avg

±6.4%

Pricing rich

The options market is pricing in a significant potential move, reflecting uncertainty and anticipation surrounding the earnings report.

Options are pricing ±19.8% while ALNY has averaged ±6.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

30.3%

Calls (21K)P/C Ratio: 0.89Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Alnylam beats expectations, history suggests the stock could rise by around 1.45%, confirming strong operational momentum.

In-Line / Cautious

A cautious inline report could lead to muted reactions, as investors weigh management's commentary against high expectations.

Miss

If the company misses expectations, history suggests a potential decline of around 6.65%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of new RNAi therapies in the pipeline.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on operational efficiencies and cost management strategies.
4Insights into market demand for their existing products.
5Any commentary on competitive landscape and market positioning.